A randomised phase III trial of high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy.

The purpose of this study is to investigate whether adding chemotherapy to a short (less than six weeks) course of radiotherapy results in a greater improvement in symptoms and overall wellbeing (quality of life) compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC) who cannot be treated with surgery or a long (six weeks or longer) course of radiotherapy and chemotherapy.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

76

Trial Chairperson

Associate Professor Margot Lehman, Princess Alexandra Hospital, QLD

Clinical Trial Registration

Related Post

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof